Want to join the conversation?
Latham, New York-based $ANGO said in 4Q16 the company successfully launched the new Asclera varicose and spider vein treatments and benefited from additional volume as a result of the Cook Medical recall. Growth in the Oncology/Surgery International business was driven by the approval of NanoKnife Probes in China.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.